Cargando…

Tumor neutrophils ferroptosis: a targetable immunosuppressive mechanism for cancer immunotherapy

Detalles Bibliográficos
Autores principales:	Du, Songtao, Zeng, Furong, Deng, Guangtong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947168/ https://www.ncbi.nlm.nih.gov/pubmed/36813764 http://dx.doi.org/10.1038/s41392-023-01357-z

Ejemplares similares

The anti-ferroptotic role of FSP1: current molecular mechanism and therapeutic approach
por: Zeng, Furong, et al.
Publicado: (2022)

Neutrophil-sourced TNF in cancer: deciphering an intricate orchestrator of immunosuppressive communication in the tumor microenvironment
por: Zhao, Xinyuan, et al.
Publicado: (2023)

Pretreatment neutrophil-to-lymphocyte ratio predicts the benefit of gastric cancer patients with systemic therapy
por: Du, Songtao, et al.
Publicado: (2021)

Dysregulated neutrophilic cell death in SLE: a spotlight on ferroptosis
por: Ohl, Kim, et al.
Publicado: (2021)

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy [Image: see text]
por: Borst, Jannie, et al.
Publicado: (2021)

Prognostic and therapeutic significance of a novel ferroptosis related signature in colorectal cancer patients
por: Du, Songtao, et al.
Publicado: (2022)

Targeting FMRP: A new window for cancer immunotherapy
por: Zhang, Yaguang, et al.
Publicado: (2023)

Tumor‐derived microparticles in tumor immunology and immunotherapy
por: Ma, Jingwei, et al.
Publicado: (2020)

Disulfidptosis: a new form of regulated cell death for cancer treatment
por: Meng, Yu, et al.
Publicado: (2023)

The Prognostic Significance of Baseline Neutrophil-to-Lymphocyte Ratio in Melanoma Patients Receiving Immunotherapy
por: Li, Yayun, et al.
Publicado: (2022)

Targeting Ferroptosis by Ubiquitin System Enzymes: A Potential Therapeutic Strategy in Cancer
por: Meng, Yu, et al.
Publicado: (2022)

Antigen targeting to dendritic cells: Still a place in future immunotherapy?
por: Stoitzner, Patrizia, et al.
Publicado: (2022)

A novel mechanism of ferroptosis surveillance offers promising therapeutic avenues for breast and prostate cancers
por: Xu, Rongyang, et al.
Publicado: (2023)

High hopes and high honours for cancer immunotherapy
por: Häfner, Sophia Julia
Publicado: (2019)

ACSL4, PUFA, and ferroptosis: new arsenal in anti-tumor immunity
por: Gan, Boyi
Publicado: (2022)

New strategies for cancer immunotherapy: targeting regulatory T cells
por: Finotello, Francesca, et al.
Publicado: (2017)

Neutrophil activation and neutrophil extracellular traps (NETs) in COVID‐19 ARDS and immunothrombosis
por: Cesta, Maria Candida, et al.
Publicado: (2022)

Ferroptosis: the Good, the Bad and the Ugly
por: Aldrovandi, Maceler, et al.
Publicado: (2020)

Peroxisome: the new player in ferroptosis
por: Tang, Daolin, et al.
Publicado: (2020)

An effective platform for cancer immunotherapy: pooled knockin targeting for genome engineering
por: Jin, Ke, et al.
Publicado: (2020)

Targeting PCSK9: a promising adjuvant strategy in cancer immunotherapy
por: Almeida, Catarina R., et al.
Publicado: (2021)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Pharmacologic RNA splicing modulation: a novel mechanism to enhance neoantigen-directed anti-tumor immunity and immunotherapy response
por: Elliott, Kerryn, et al.
Publicado: (2021)

Uncovering the IL‐1β‐PCAF‐NNT axis: A new player in ferroptosis and tumor immune evasion
por: Li, Qidong, et al.
Publicado: (2023)

Constant regulation for stable CD8 T‐cell functional avidity and its possible implications for cancer immunotherapy
por: Gilfillan, Connie B., et al.
Publicado: (2021)

The risk of developing second primary malignancies among colorectal cancer patients
por: Du, Songtao, et al.
Publicado: (2022)

Cancer Environment Immunotherapy: targeting TGF-β finds its way towards tissue healing and vasculature remodeling
por: Jin, Ke, et al.
Publicado: (2021)

ecDNA within tumors: a new mechanism that drives tumor heterogeneity and drug resistance
por: Zeng, Xixi, et al.
Publicado: (2020)

Methionine restriction sensitizes cancer cells to immunotherapy
por: Lu, Weiqin, et al.
Publicado: (2023)

A ‘fit’ microbiota to potentiate cancer immunotherapy
por: Rescigno, Maria
Publicado: (2015)

Normalization cancer immunotherapy: blocking Siglec-15!
por: Cao, Guangchao, et al.
Publicado: (2019)

Inhibiting SCD expression by IGF1R during lorlatinib therapy sensitizes melanoma to ferroptosis
por: Zeng, Furong, et al.
Publicado: (2023)

Sell(hi) neutrophils: a key to triumph in cancer therapy
por: Pylaeva, Ekaterina, et al.
Publicado: (2023)

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
por: Tian, Xinyu, et al.
Publicado: (2023)

FcγRIIb blockage: a promising immunotherapy target for severe COVID-19
por: He, Xuemei, et al.
Publicado: (2021)

Chromatin remodeling factor lymphoid-specific helicase inhibits ferroptosis through lipid metabolic genes in lung cancer progression
por: Jiang, Yiqun, et al.
Publicado: (2017)

STING cg16983159 methylation: a key factor for glioblastoma immunosuppression
por: Qiu, Lei, et al.
Publicado: (2022)

Targeting chemokines/chemokine receptors: a promising strategy for enhancing the immunotherapy of pancreatic ductal adenocarcinoma
por: Gong, Ruining, et al.
Publicado: (2020)

Doubling down with CAR-T cell cancer immunotherapy: a two-step recognition circuit enables discrimination between target antigen high and low cancer cells
por: Charo, Jehad, et al.
Publicado: (2021)

Combined immunotherapy for advanced prostate cancer: Empowering the T cell army
por: Suleman, Sufyan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5113s68s8f7s8d8k5oqtgedemc